We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

117 hedge funds and large institutions have $476M invested in Intra-Cellular Therapies Inc. in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 38 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more call options, than puts

Call options by funds: $4.41M | Put options by funds: $2.9M

5% more capital invested

Capital invested by funds: $454M → $476M (+$22M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less funds holding

Funds holding: 129 → 117 (-12)

11% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 38

32% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 22

Holders
117
Holders Change
-12
Holders Change %
-9.3%
% of All Funds
2.91%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
34
Reduced
38
Closed
22
Calls
$4.41M
Puts
$2.9M
Net Calls
+$1.5M
Net Calls Change
-$2.71M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$51.5M
2
CCP
Clough Capital Partners
Massachusetts
+$7.95M
3
RPAM
Rhenman & Partners Asset Management
Sweden
+$6.16M
4
BB
BB Biotech
Switzerland
+$5.07M
5
SC
Samlyn Capital
New York
+$4.9M

Top Sellers

Rank Fund Capital Flow
1
TCM
TimesSquare Capital Management
New York
-$23.2M
2
Jennison Associates
Jennison Associates
New York
-$15.5M
3
Citadel Advisors
Citadel Advisors
Florida
-$6.7M
4
BIM
Bogle Investment Management
Massachusetts
-$4.23M
5
CCI
Columbus Circle Investors
-$2M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
101
Ameritas Investment Partners
Nebraska
$48K +$42.9K +2,964 New
Barclays
102
Barclays
United Kingdom
$37K -$8.26K -571 -20%
BCM
103
Blume Capital Management
California
$16K – – –
Zurich Cantonal Bank
104
Zurich Cantonal Bank
Switzerland
$15K – – –
Creative Planning
105
Creative Planning
Kansas
$15K +$12.2K +845 +1,536%
BNP Paribas Financial Markets
106
BNP Paribas Financial Markets
France
$12.3K -$4.92K -340 -31%
MAM
107
Meeder Asset Management
Ohio
$12K -$18.4K -1,268 -63%
IA
108
IFP Advisors
Florida
$5K – – –
AP
109
Atwood & Palmer
Missouri
$3K – – –
SBL
110
Sargent Bickham Lagudis
Colorado
$3K – – –
Simplex Trading
111
Simplex Trading
Illinois
$2K -$265K -18,321 -99%
GXMC
112
Global X Management Company
New York
$2K – – –
LTFS
113
Ladenburg Thalmann Financial Services
Florida
$2K – – –
UBS Group
114
UBS Group
Switzerland
$2K – – –
US Bancorp
115
US Bancorp
Minnesota
$2K +$449 +31 +48%
GEA
116
Glen Eagle Advisors
New Jersey
$1.63K +$1.45K +100 New
TCM
117
TimesSquare Capital Management
New York
– -$23.2M -1,534,938 Closed
Jennison Associates
118
Jennison Associates
New York
– -$15.5M -1,024,366 Closed
SEI Investments
119
SEI Investments
Pennsylvania
– -$1.69M -112,000 Closed
OAM
120
Oxford Asset Management
United Kingdom
– -$728K -48,254 Closed
SCM
121
Suffolk Capital Management
New York
– -$703K -46,564 Closed
VKH
122
Virtu KCG Holdings
New York
– -$458K -30,368 Closed
LCM
123
Landscape Capital Management
New Jersey
– -$351K -23,230 Closed
Squarepoint
124
Squarepoint
New York
– -$306K -20,270 Closed
SG Americas Securities
125
SG Americas Securities
New York
– -$281K -18,608 Closed
2 3 4
5
6

ITCI Hedge Fund Activity: Q1 2017 in Review

117 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2017, worth a combined $476M — up 4.8% from $454M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ITCI and 15 opened new positions — a net loss of 7 holders — while 38 trimmed existing stakes and 34 added.

The largest buyer was BlackRock, adding an estimated $51.5M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $23.2M sold.

  • 117 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2017, down from 129 in Q4 2016.
  • Funds reported $476M of Intra-Cellular Therapies Inc. stock for Q1 2017, up 4.8% quarter-over-quarter.
  • 15 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2017 and 22 closed out, a net change of -7 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2017 was BlackRock, an estimated $51.5M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q1 2017 was TimesSquare Capital Management, an estimated $23.2M sold.

Based on aggregated 13F filings for Q1 2017.